Evidence map›Paper›PMID 27579370›Full record

ArticlemSphere

A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence.

Daniel R Kirienko, Alexey V Revtovich, Natalia V Kirienko

Open access · goldAbstract read
In one paragraph

Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Microbiology spectrum · 2026
    Article
  4. Article
  5. Host-mimicking conditions promoteFrontiers in microbiology · 2025
    Article
  6. Effect of 5-fluorouracil onFrontiers in microbiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Microbiology spectrum · 2024
    Article
  11. Article
  12. bioRxiv : the preprint server for biology · 2023
    Article
  13. Article
  14. Review
  15. Exploring a chemical scaffold for rapid and selective photoaffinity labelling of non-ribosomal peptide synthetases in living bacterial cells.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  16. Treatment with paeoniflorin increases lifespan ofFrontiers in pharmacology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Daniel R KirienkoDepartment of BioSciences, Rice University, Houston, Texas, USA.
Alexey V RevtovichDepartment of BioSciences, Rice University, Houston, Texas, USA.
Natalia V KirienkoDepartment of BioSciences, Rice University, Houston, Texas, USA.ORCID 0000-0002-1537-4967
Rice University · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI CLARDY, JON · 2003 to 2013
$113.7M
Identifying novel anti-infectives by high through-put screening in whole animalsR01AI085581 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI AUSUBEL, FREDERICK M · 2009 to 2013
$4.7M
Mechanisms of Stimulating Innate ImmunityK22AI110552 · NIAID · RICE UNIVERSITY · PI KIRIENKO, NATASHA · 2015 to 2016
$268k
Utilizing a novel liquid-killing assay to gain insight into C. elegans immunityF32AI100501 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIRIENKO, NATASHA · 2012 to 2014
$163k
NIAID NIH HHS F32 AI100501NIAID NIH HHS K22 AI110552NIAID NIH HHS R01 AI085581NIAID NIH HHS U54 AI057159
6 · The paper itself

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen that causes severe health problems. Despite intensive investigation, many aspects of microbial virulence remain poorly understood. We used a high-throughput, high-content, whole-organism, phenotypic screen to identify small molecules that inhibit P. aeruginosa virulence in Caenorhabditis elegans. Approximately half of the hits were known antimicrobials. A large number of hits were nonantimicrobial bioactive compounds, including the cancer chemotherapeutic 5-fluorouracil. We determined that 5-fluorouracil both transiently inhibits bacterial growth and reduces pyoverdine biosynthesis. Pyoverdine is a siderophore that regulates the expression of several virulence determinants and is critical for pathogenesis in mammals. We show that 5-fluorouridine, a downstream metabolite of 5-fluorouracil, is responsible for inhibiting pyoverdine biosynthesis. We also show that 5-fluorouridine, in contrast to 5-fluorouracil, is a genuine antivirulence compound, with no bacteriostatic or bactericidal activity. To our knowledge, this is the first report utilizing a whole-organism screen to identify novel compounds with antivirulent properties effective against P. aeruginosa. IMPORTANCE Despite intense research effort from scientists and the advent of the molecular age of biomedical research, many of the mechanisms that underlie pathogenesis are still understood poorly, if at all. The opportunistic human pathogen Pseudomonas aeruginosa causes a variety of soft tissue infections and is responsible for over 50,000 hospital-acquired infections per year. In addition, P. aeruginosa exhibits a striking degree of innate and acquired antimicrobial resistance, complicating treatment. It is increasingly important to understand P. aeruginosa virulence. In an effort to gain this information in an unbiased fashion, we used a high-throughput phenotypic screen to identify small molecules that disrupted bacterial pathogenesis and increased host survival using the model nematode Caenorhabditis elegans. This method led to the unexpected discovery that addition of a modified nucleotide, 5-fluorouridine, disrupted bacterial RNA metabolism and inhibited synthesis of pyoverdine, a critical toxin. Our results demonstrate that this compound specifically functions as an antivirulent.

Indexed as

5-fluorouracil5-fluorouridineCaenorhabditis eleganshigh-throughput screeningPseudomonas aeruginosapyoverdinesiderophoresvirulence determinants

Identifiers

PMID27579370
PMCPMC4999921
OpenAlexW2508853891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.